Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Barinthus Biotherapeutics (BRNS) Shares Issued (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Shares Issued for 4 consecutive years, with -$2000.0 as the latest value for Q2 2025.

For Q2 2025, Shares Issued rose 99.6% year-over-year to -$2000.0; the TTM value through Mar 2026 reached -$2000.0, down 100.12%, while the annual FY2024 figure was $2.2 million, 6.29% up from the prior year.
Shares Issued hit -$2000.0 in Q2 2025 for Barinthus Biotherapeutics, down from $2000.0 in the prior quarter.
Across five years, Shares Issued topped out at $102.8 million in Q2 2021 and bottomed at -$102.8 million in Q4 2021.
Average Shares Issued over 4 years is $382454.5, with a median of $109000.0 recorded in 2023.
Year-over-year, Shares Issued surged 1884.4% in 2024 and then tumbled 99.6% in 2025.
Barinthus Biotherapeutics' Shares Issued stood at -$102.8 million in 2021, then soared by 100.11% to $109000.0 in 2023, then soared by 1884.4% to $2.2 million in 2024, then crashed by 100.09% to -$2000.0 in 2025.
According to Business Quant data, Shares Issued over the past three periods came in at -$2000.0, $2000.0, and $2.2 million for Q2 2025, Q1 2025, and Q4 2024 respectively.